The Oncologica Team

Leading specialists in the oncopathology field, Oncologica® maintains a highly skilled, dedicated team of professionals

Paul Scorer is Principal Scientist Histology at Oncologica

Paul joined Oncologica® in March 2021 as Principal Scientist in Histology. He is responsible for delivering histology and immunocytochemistry (ICC) testing, part of Oncologica®’s clinical oncology genetic sequencing service offered to cancer patients. Paul also has a role in co-ordinating research focused on correlation of Oncologica® sequencing results and patient response and the development of diagnostic tests linked to therapeutic intervention strategies.

Paul has over 40 years experience in all aspects of clinical histology/ICC, diagnostics testing, pharmaceutical development, project leading and quality control. Paul began his career in histopathology at the Queen Elizabeth Hospital in Gateshead where he spent 25 years, including 18 years as senior BMS running the ICC service. Paul moved to private industry joining Vision Biosystems (Novocastra Laboratories) in Newcastle (subsequently Leica Biosystems) spending 12 years in QC, R&D and clinical assay development. In 2015 Paul joined the pharmaceutical company AstraZeneca in Cambridge, spending 6 years as Associate Principal Scientist in Precision Medicine mainly focused on drug therapies and ICC assays targeting PD-L1 expression in tumours.

Paul is an Executive Board Member of UK NEQAS CPT, an EQA assessor and responsible for annually delivering histology specialist staining techniques and ICC educational lectures/workshops for UKNEQAS CPT.

Published Research Papers

Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer

Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer

J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33664-0. doi: https://doi.org/10.1016/j.jtho.2019.11.010.

Williams GH, Nicholson AG, Snead DRJ, Thunnissen E, Lantuejoul S, Cane P, Kerr KM, Loddo M, Scott MLJ, Scorer PW, Barker C. (2019)

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Mod Pathol. 2019 Sep 26. doi: https://doi.org/10.1038/s41379-019-0372-z. [Epub ahead of print] Erratum in: Mod Pathol. 2019 Oct

Lawson NL, Dix CI, Scorer PW, Stubbs CJ, Wong E, Hutchinson L, McCall EJ, Schimpl M, DeVries E, Walker J, Williams GH, Hunt J, Barker C. (2019)

Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.

Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.

Nature – Scientific Reports, April 2017, 7, 45938 DOI: https://doi.org/10.1038/srep45938

Michel E. Vandenberghe, Marietta L. J. Scott, Paul W. Scorer et al (2017)